The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://kaleowgs148627.wikiadvocate.com/32339/glp_3_retatrutide_a_comparative_analysis